Drug Search Results
More Filters [+]

Lamotrigine

Alternative Names: lamotrigine, lamictal, bw430c, gi-267119, gi267119, gi 267119, gi 267119x, gi -67119x, gi267119x, lamictal cd, lamotrigin, subvenite
Latest Update: 2024-02-09
Latest Update Note: Clinical Trial Update

Product Description

Lamotrigine (Lamictal), a phenyltriazine derivative, is a well established anticonvulsant agent that has shown efficacy in the prevention of mood episodes in adult patients with bipolar I disorder. The mechanism of action of the drug in patients with bipolar disorder may be related to the inhibition of sodium and calcium channels in presynaptic neurons and subsequent stabilisation of the neuronal membrane. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12962521/)

Mechanisms of Action: HCN Agonist,Calcium Channel Blocker,Sodium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Epilepsy | Epilepsy, Generalized | Lennox Gastaut Syndrome | Seizures | Bipolar Disorder | Conversion Disorder | Seizures

Known Adverse Events: Epilepsy | Bipolar Disorder | Abdominal Pain | Ataxia | Back Pain | Diplopia | Dizziness | Headache | Pain Unspecified | Tremor | Insomnia | Xerostomia | Pharyngitis | Rhinitis | Diarrhea

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lamotrigine

Countries in Clinic: Canada, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Bipolar Disorder|Epilepsy|Seizures

Phase 2: Dizziness|Meniere Disease|Vertigo

Phase 1: Healthy Volunteers|Tobacco Use Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DBTC-003

P2

Recruiting

Dizziness|Meniere Disease|Vertigo

2024-07-01

LTG-008/K

P1

Completed

Tobacco Use Disorder

2023-05-09

43%

2016-004954-13

P3

Active, not recruiting

Epilepsy

2022-10-05

Open study of Lamictal monotherapy for children with absence seizures

P3

Active, not recruiting

Seizures

2022-09-18

Recent News Events